Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.
Aredo JV, Wakelee HA, Ramchandran KJ, Neal JW, Diehn M, Hui AB, Salahudeen A, Kwong B, Berry GJ, Guo HH, Cunanan K, Vali S, Pancirer D, Tsang V, Hwang G, Loza M, Johnson B, Blanchard I, Padda SK. Aredo JV, et al. JTO Clin Res Rep. 2024 Oct 17;5(12):100741. doi: 10.1016/j.jtocrr.2024.100741. eCollection 2024 Dec. JTO Clin Res Rep. 2024. PMID: 39624248 Free PMC article.
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.
McDaid WJ, Wilson L, Adderley H, Martinez-Lopez A, Baker MJ, Searle J, Ginn L, Budden T, Aldea M, Marinello A, Aredo JV, Viros A, Besse B, Wakelee HA, Blackhall F, Castillo-Lluva S, Lindsay CR, Malliri A. McDaid WJ, et al. Among authors: aredo jv. Mol Cancer. 2024 Nov 12;23(1):253. doi: 10.1186/s12943-024-02157-x. Mol Cancer. 2024. PMID: 39533328 Free PMC article.
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Nassar AH, et al. Among authors: aredo jv. J Thorac Oncol. 2024 Sep 10:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Online ahead of print. J Thorac Oncol. 2024. PMID: 39260522
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM. Blakely CM, et al. Among authors: aredo jv. J Clin Oncol. 2024 Sep 10;42(26):3105-3114. doi: 10.1200/JCO.24.00071. Epub 2024 Jul 19. J Clin Oncol. 2024. PMID: 39028931 Free PMC article. Clinical Trial.
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Nassar AH, et al. Among authors: aredo jv. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. J Thorac Oncol. 2024. PMID: 38278303
Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.
Choi E, Su CC, Wu JT, Aredo JV, Neal JW, Leung AN, Backhus LM, Lui NS, Le Marchand L, Stram DO, Liang SY, Cheng I, Wakelee HA, Han SS. Choi E, et al. Among authors: aredo jv. JAMA Netw Open. 2023 Nov 1;6(11):e2343278. doi: 10.1001/jamanetworkopen.2023.43278. JAMA Netw Open. 2023. PMID: 37966839 Free PMC article.
Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
Choi E, Ding VY, Luo SJ, Ten Haaf K, Wu JT, Aredo JV, Wilkens LR, Freedman ND, Backhus LM, Leung AN, Meza R, Lui NS, Haiman CA, Park SL, Le Marchand L, Neal JW, Cheng I, Wakelee HA, Tammemägi MC, Han SS. Choi E, et al. Among authors: aredo jv. JAMA Oncol. 2023 Dec 1;9(12):1640-1648. doi: 10.1001/jamaoncol.2023.4447. JAMA Oncol. 2023. PMID: 37883107 Free PMC article.
Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
Choi E, Luo SJ, Ding VY, Wu JT, Kumar AV, Wampfler J, Tammemägi MC, Wilkens LR, Aredo JV, Backhus LM, Neal JW, Leung AN, Freedman ND, Hung RJ, Amos CI, Le Marchand L, Cheng I, Wakelee HA, Yang P, Han SS. Choi E, et al. Among authors: aredo jv. Cancer. 2024 Mar 1;130(5):770-780. doi: 10.1002/cncr.35069. Epub 2023 Oct 25. Cancer. 2024. PMID: 37877788
38 results